Adlai Nortye (ANL) Q4 2024 earnings summary

Executive summary

• Focused on innovative cancer therapies, with a robust pipeline led by AN2025, a pan-PI3K inhibitor in Phase III for HNSCC post anti-PD-1/PD-L1 therapy, and several other candidates in various stages of development.

• Completed patient enrollment for the pivotal Phase III AN2025 trial in November 2023; topline results expected Q2 2025, with NDA submission planned for H2 2025.

• AN4005, an oral PD-L1 inhibitor, advanced to Phase I expansion; AN8025 and AN9025 are in IND-enabling stages.

• No product revenue to date; operations funded by equity, debt, and government grants.

Financial highlights

• Net loss for 2024 was $51.9 million, a significant improvement from $109.2 million in 2023, mainly due to lower R&D and administrative expenses.

• R&D expenses decreased 22.8% year-over-year to $44.9 million, reflecting completion of AN2025 Phase III enrollment.

• Administrative expenses fell 34.9% to $10.0 million, primarily due to lower IPO-related costs and share-based compensation.

• Cash and cash equivalents at year-end 2024 were $60.9 million.

• No revenue from product sales; other income mainly from government grants.

• No dividends declared or paid.

Outlook and guidance

• Sufficient cash runway for at least 12 months, but continued losses and negative cash flow from operations expected until product commercialization.

• Topline Phase III data for AN2025 expected in Q2 2025; NDA submission planned for H2 2025.

• Ongoing need for additional funding through equity, debt, or partnerships to support R&D and commercialization.